Sotera Health (SHC) just delivered a busy first quarter, pairing 10% year-over-year revenue growth and a move back to profitability with reaffirmed 2026 guidance and a planned CEO transition.

The share price is US$15.67 after a 7.04% 1 month share price return. However, the 90 day share price return of 11.72% and year to date share price return of 11.42% suggest recent momentum has cooled. Even so, the 1 year total shareholder return of 18.44% and 3 year total shareholder return of 6.09% contrast with a 5 year total shareholder return of 27.45%. This highlights that recent earnings beats, reaffirmed 2026 guidance and the incoming CEO are being weighed against longer term legal and leverage risks.

If Sotera’s Q1 beat has you thinking about other healthcare names tied to medical technology and services, it could be a good moment to scan 35 healthcare AI stocks

With SHC trading at US$15.67 alongside an indicated intrinsic discount and a sizeable gap to analyst targets, the key question is whether investors are overlooking earnings momentum and the incoming CEO, or whether the stock already reflects future growth.

Most Popular Narrative: 23.6% Undervalued

With Sotera Health trading at $15.67 against a narrative fair value of $20.50, the market price currently sits well below that framework.

The analysts have a consensus price target of $20.5 for Sotera Health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $24.0, and the most bearish reporting a price target of just $16.0.

Curious what kind of earnings ramp, margin shift and valuation multiple are built into that target, and how tightly analysts cluster around those assumptions.

Result: Fair Value of $20.50 (UNDERVALUED)

However, you still need to weigh ongoing EtO litigation and compliance costs, as well as elevated CapEx plans through 2027, which could pressure margins and limit financial flexibility.

Another Way to Look at the Price

The earlier narrative points to Sotera Health trading below an estimated fair value of $20.50, but the P/E ratio of 37.9x tells a different story. It sits slightly above the global Life Sciences average of 37.1x and well above the fair ratio of 22.4x, suggesting less margin for error if earnings or sentiment slip. Which lens do you trust more when the signals do not fully line up?

Next Steps

With mixed signals on valuation and sentiment running both hot and cold, it makes sense to look at the underlying data directly and decide quickly where you stand. To weigh the upside potential against the issues that are worrying investors, review the 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop with a single stock, you risk missing other opportunities that fit your style. Use the screener to line up your next few candidates.

• Target quality at a discount by scanning 51 high quality undervalued stocks that pair solid fundamentals with room for a rerating.
• Prioritize resilience and focus on 71 resilient stocks with low risk scores that historically show fewer red flags.
• Spot potential future leaders early by reviewing the screener containing 23 high quality undiscovered gems before they get crowded.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.